Inhibikase Therapeutics (IKT) Gains from Investment Securities (2020 - 2026)

Inhibikase Therapeutics (IKT) has 7 years of Gains from Investment Securities data on file, last reported at $11.6 million in Q1 2026.

• Gains from Investment Securities for Q1 2026 came in at $11.6 million, down 45.48% year-over-year; the trailing twelve-month figure through Mar 2026 was $11.6 million (down 45.48% YoY), and the FY2024 annual result was $1.1 million, up 42.52% from the prior year.
• Gains from Investment Securities fell to $11.6 million in Q1 2026 per IKT's latest filing, from $27.2 million in the prior quarter.
• Over five years, Gains from Investment Securities peaked at $27.2 million in Q3 2025 and troughed at $18039.0 in Q1 2024.
• A 5-year average of $6.3 million and a median of $248039.0 in 2024 frame the typical range for Gains from Investment Securities.
• The sharpest annual moves came in 2024 and 2025: Gains from Investment Securities sank 63.92% in 2024, then jumped 118139.34% in 2025.
• A 5-year view of Gains from Investment Securities shows it stood at $76651.0 in 2022, then jumped by 944.07% to $800293.0 in 2023, then soared by 42.52% to $1.1 million in 2024, then surged by 2286.98% to $27.2 million in 2025, then slumped by 57.29% to $11.6 million in 2026.
• Business Quant data shows IKT's Gains from Investment Securities at $11.6 million in Q1 2026, $27.2 million in Q3 2025, and $25.8 million in Q2 2025.